Analysts Offer Predictions for VRDN Q1 Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Stock analysts at B. Riley issued their Q1 2025 earnings estimates for Viridian Therapeutics in a research report issued on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will post earnings of ($1.09) per share for the quarter. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. B. Riley also issued estimates for Viridian Therapeutics’ Q3 2025 earnings at ($1.21) EPS, Q4 2025 earnings at ($1.30) EPS, FY2025 earnings at ($4.74) EPS, FY2026 earnings at ($4.95) EPS, FY2027 earnings at ($3.61) EPS and FY2028 earnings at ($2.64) EPS.

Other analysts have also recently issued reports about the stock. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a report on Monday, December 16th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $27.00 price target (down previously from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Royal Bank of Canada boosted their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Tuesday, December 17th. Finally, TD Cowen started coverage on Viridian Therapeutics in a report on Monday, November 25th. They set a “buy” rating on the stock. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $35.70.

Viridian Therapeutics Trading Up 0.3 %

Shares of NASDAQ VRDN opened at $15.28 on Wednesday. The business has a 50 day simple moving average of $17.94 and a 200 day simple moving average of $19.67. Viridian Therapeutics has a 52 week low of $11.40 and a 52 week high of $27.20. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -3.55 and a beta of 1.32. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The firm had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.05 million.

Institutional Trading of Viridian Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Great Point Partners LLC raised its position in shares of Viridian Therapeutics by 50.0% during the third quarter. Great Point Partners LLC now owns 750,000 shares of the company’s stock valued at $17,062,000 after buying an additional 250,000 shares during the last quarter. Lord Abbett & CO. LLC acquired a new position in Viridian Therapeutics in the 3rd quarter valued at approximately $8,917,000. JPMorgan Chase & Co. lifted its position in shares of Viridian Therapeutics by 218.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company’s stock worth $9,108,000 after acquiring an additional 274,641 shares during the period. Barclays PLC grew its holdings in shares of Viridian Therapeutics by 113.1% during the 3rd quarter. Barclays PLC now owns 125,397 shares of the company’s stock worth $2,851,000 after purchasing an additional 66,550 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Viridian Therapeutics during the 3rd quarter worth approximately $788,000.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.